We use cookies to ensure that we give you the best experience on your website. If you continue without changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 15 June 2016
BTG plc (LSE: BTG), the specialist healthcare company, is pleased to announce that it has completed the acquisition of Galil Medical, a leading provider of cryoablation products for the treatment of kidney and other cancers. BTG announced on 6 May 2016 that it had entered into an agreement to acquire Galil. For further information contact: BTG Andy Burrows, VP Corporate & Investor Relations +44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605 Stuart Hunt, Investor Relations Manager +44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536 Chris Sampson, Corporate Communications Director +44 20 7575 1595; Mobile: +44 7773 251 178 FTI Consulting Ben Atwell/Simon Conway +44 (0)20 3727 1000